Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics
Cumberland Pharmaceuticals Inc. (CPIX)
Today's Latest Price: $3.20 USD
Updated Sep 29 4:00pm
Add CPIX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CPIX Stock Summary
- Cumberland Pharmaceuticals Inc's market capitalization of $49,806,070 is ahead of only 14.07% of US-listed equities.
- For CPIX, its debt to operating expenses ratio is greater than that reported by 28.77% of US equities we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CPIX comes in at 13.12% -- higher than that of 83.65% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Cumberland Pharmaceuticals Inc are MMSI, INTT, TACT, PLPC, and NSSC.
- Visit CPIX's SEC page to see the company's official filings. To visit the company's web site, go to www.cumberlandpharma.com.
CPIX Stock Price Chart Technical Analysis Charts
CPIX Price/Volume Stats
| Current price | $3.20 | 52-week high | $6.10 |
| Prev. close | $3.29 | 52-week low | $3.10 |
| Day low | $3.18 | Volume | 6,099 |
| Day high | $3.25 | Avg. volume | 28,356 |
| 50-day MA | $3.29 | Dividend yield | N/A |
| 200-day MA | $3.88 | Market Cap | 48.44M |
Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
CPIX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $3.20 | $1.53 | -54% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Cumberland Pharmaceuticals Inc. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 27th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 53.33%. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is -18.66; that's higher than only 7.22% of US stocks in the Healthcare sector that have positive free cash flow.
- Cumberland Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -54% |
| 1% | -54% |
| 2% | -54% |
| 3% | -53% |
| 4% | -53% |
| 5% | -52% |
PKI, RMD, XRAY, ZTS, and ILMN can be thought of as valuation peers to CPIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...